Teva Pharmaceutical Industries (TEVA) filed a registration statement with the US Securities and Exchange Commission Friday for the sale of securities by the company and its finance subsidiaries.
The prospectus includes American depositary shares each representing one ordinary share, debt securities, purchase contracts and units.
Proceeds from the sale of securities will be used for general corporate purposes including working capital, investments in, or extensions of credit to Teva's units and repay debt, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。